<DOC>
	<DOCNO>NCT02959749</DOCNO>
	<brief_summary>Acquired epidermal growth factor receptor ( EGFR ) T790M mutation common genetic change resistant first generation EGFR tyrosine kinase inhibitor ( EGFR TKI ) non-small cell lung cancer . After 10 14 month median progression-free survival treatment first generation EGFR TKI , half patient get disease progression.For patient progression treat first line EGFR TKI second line double bullet chemotherapy chemotherapy EGFR TKI , optimal third line therapy quite critical important benefit patient ' survival . We conduct study aim compare efficacy toxicity osimertinib docetaxel-bevacizumab third line therapy patient local advance metastatic non-squamous cell lung cancer .</brief_summary>
	<brief_title>Osimertinib Docetaxel-bevacizumab Third-line Treatment EGFR T790M Mutated Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>local advance metastatic nonsmall cell lung cancer large cell lung carcinoma adenocinoma Previously treat TKIChemotherapy ChemotherapyTKI EGFR T790M positive No uncontrolled hypertension No active bleeding thrombosis recent 6 month No previously treat VEGF antibody newly diagnose thrombosis anticoagulation therapy uncontrolled hypertension uncontrolled nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Osimertinib</keyword>
	<keyword>EGFR T790M Resistant Mutation</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Non Small Cell Lung</keyword>
</DOC>